Stockscreener 앱 받기
9.79
0.93%
0.09
시간 외 거래:
9.50
-0.29
-2.96%
전일 마감가:
$9.70
열려 있는:
$9.78
하루 거래량:
157.94K
Relative Volume:
1.08
시가총액:
$119.98M
수익:
$1.54M
순이익/손실:
$-38.70M
주가수익비율:
-2.0964
EPS:
-4.67
순현금흐름:
$-36.86M
1주 성능:
+5.84%
1개월 성능:
+12.53%
6개월 성능:
+19.68%
1년 성능:
-83.55%
1일 변동 폭
$9.5048
$10.18
1주일 범위
$8.88
$10.18
52주 변동 폭
$4.64
$61.72
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
명칭
Corbus Pharmaceuticals Holdings Inc
전화
617-963-0103
주소
500 RIVER RIDGE DRIVE, NORWOOD, MA
CRBP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
9.79 | 113.36M | 1.54M | -38.70M | -36.86M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-30 | 재개 | B. Riley Securities | Buy |
| 2025-02-28 | 개시 | William Blair | Outperform |
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 개시 | Wedbush | Outperform |
| 2024-07-22 | 재개 | H.C. Wainwright | Buy |
| 2024-06-26 | 개시 | B. Riley Securities | Buy |
| 2024-06-03 | 재확인 | Oppenheimer | Outperform |
| 2024-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2024-03-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-08 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-09-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-09-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-07-07 | 개시 | ROTH Capital | Buy |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-03-26 | 개시 | Nomura | Buy |
| 2019-04-05 | 개시 | Jefferies | Buy |
| 2019-03-20 | 개시 | Oppenheimer | Outperform |
| 2019-01-11 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-12-26 | 개시 | H.C. Wainwright | Buy |
| 2018-12-07 | 개시 | RBC Capital Mkts | Outperform |
| 2018-10-24 | 개시 | B. Riley FBR | Buy |
| 2018-01-19 | 개시 | Raymond James | Outperform |
| 2017-12-14 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-11-08 | 재확인 | Noble Financial | Buy |
| 2017-09-29 | 재개 | Noble Financial | Buy |
| 2017-03-30 | 재확인 | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-11-11 | 재확인 | Noble Financial | Buy |
모두보기
Corbus Pharmaceuticals Holdings Inc 주식(CRBP)의 최신 뉴스
Volume Surge May Signal Institutional Interest in Corbus Pharmaceuticals Holdings Inc.July 2025 Setups & Community Driven Trade Alerts - beatles.ru
Published on: 2025-08-17 09:14:34 - metal.it
Published on: 2025-08-16 20:39:17 - metal.it
Published on: 2025-08-16 18:59:42 - metal.it
Can Corbus Pharmaceuticals Holdings Inc. keep up with sector leadersJuly 2025 Macro Moves & Smart Swing Trading Alerts - thegnnews.com
Fibonacci Support Holding Strong in Corbus Pharmaceuticals Holdings Inc.Trade Volume Report & AI Driven Price Predictions - kangso.co.kr
What is the next catalyst for Corbus Pharmaceuticals Holdings Inc.Free Trading Indicator Pack - thegnnews.com
Can Cannabis Stocks Reverse Their Prolonged Downtrend? - The Globe and Mail
Oppenheimer Lowers Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target to $53.00 - Defense World
Corbus Pharmaceuticals Reports Q2 2025 Financials and Updates - TipRanks
William Blair Issues Negative Outlook for CRBP Earnings - Defense World
Using flow based indicators on Corbus Pharmaceuticals Holdings Inc.Free Real Time Stock Movement Analysis - Newser
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛
How moving averages guide Corbus Pharmaceuticals Holdings Inc. tradingSwing Candidate List with Trade Cues - Newser
Oppenheimer Maintains Outperform Rating for CRBP with Lowered Price Target of $53.00 - AInvest
Oppenheimer Maintains Outperform Rating for CRBP, Lowers Price T - GuruFocus
Corbus Pharmaceuticals: Q2 Earnings Snapshot - New Haven Register
Corbus (CRBP) Q2 Loss Beats Estimates - AOL.com
Key metrics from Corbus Pharmaceuticals Holdings Inc.’s quarterly dataSummary of Long-Term Buy Zone Stocks - Newser
Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewswire
Corbus Pharmaceuticals Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Corbus Pharmaceuticals Receives FDA Fast Track Designation - TipRanks
Corbus Pharmaceuticals Q2 basic eps usd -1.44 - MarketScreener
Corbus Pharmaceuticals (CRBP) Gears Up for Pivotal Data Presentations in Late 2025 - GuruFocus
Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update | CRBP Stock News - GuruFocus
Corbus Advances 3 Clinical Programs: Obesity Drug Trial Expands, Cancer Data Coming to ESMO - Stock Titan
Is Corbus Pharmaceuticals Holdings Inc. stock overvalued or undervaluedBuild wealth steadily with smart trading - Jammu Links News
Is Corbus Pharmaceuticals Holdings Inc. a growth stock or a value stockSkyrocketing investment returns - Jammu Links News
Is Corbus Pharmaceuticals Holdings Inc. a good long term investmentFree Stock Market Return Analysis - Jammu Links News
What is the risk reward ratio of investing in Corbus Pharmaceuticals Holdings Inc. stockGet timely alerts on market opportunities - Jammu Links News
Is it the right time to buy Corbus Pharmaceuticals Holdings Inc. stockExplosive portfolio gains - Jammu Links News
What are the latest earnings results for Corbus Pharmaceuticals Holdings Inc.Superior profit margins - Jammu Links News
When is Corbus Pharmaceuticals Holdings Inc. stock expected to show significant growthDiscover breakthrough stocks before the crowd - Jammu Links News
What analysts say about Corbus Pharmaceuticals Holdings Inc. stockInvest smarter with data-backed trading alerts - Jammu Links News
What are Corbus Pharmaceuticals Holdings Inc. company’s key revenue driversFree Stock Review Backed By Experts - Jammu Links News
What is B. Riley’s Forecast for CRBP Q2 Earnings? - Defense World
What is the dividend policy of Corbus Pharmaceuticals Holdings Inc. stockFinancial News Target Finder For Smart Trading - Jammu Links News
Why is Corbus Pharmaceuticals Holdings Inc. stock attracting strong analyst attentionReal Time Tracker For Fast Growth - Jammu Links News
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Recommendation of “Buy” by Brokerages - Defense World
Corbus Pharmaceuticals stock rises after ESMO abstract acceptance By Investing.com - Investing.com Australia
Dermatomyositis Treatment Market 2034: EMA, PDMA, FDA - openPR.com
Corbus Pharmaceuticals Announces Upcoming Presentation of - GlobeNewswire
Corbus to present updated CRB-701 cancer drug data at ESMO 2025 By Investing.com - Investing.com South Africa
Corbus to present updated CRB-701 cancer drug data at ESMO 2025 - Investing.com Nigeria
Corbus Pharmaceuticals stock rises after ESMO abstract acceptance - Investing.com
CRBP: B. Riley Maintains Buy Rating with Promising Drug Potential - GuruFocus
Corbus Pharmaceuticals (CRBP) to Present Phase 1/2 Study Data at ESMO 2025 - GuruFocus
Corbus Pharmaceuticals Holdings Inc (CRBP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Corbus Pharmaceuticals Holdings Inc 주식 (CRBP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Altmeyer Anne | Director |
May 30 '25 |
Sale |
7.25 |
1,392 |
10,096 |
1,391 |
| Smethurst Dominic | Chief Medical Officer |
Mar 06 '25 |
Sale |
6.78 |
6,393 |
43,330 |
70,807 |
0.94%
1.72%
자본화:
|
볼륨(24시간):